Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$0.88 - $1.22 $6,184 - $8,574
-7,028 Reduced 94.11%
440 $0
Q1 2023

May 15, 2023

SELL
$0.91 - $1.82 $10,778 - $21,557
-11,845 Reduced 61.33%
7,468 $8,000
Q4 2022

Feb 14, 2023

SELL
$0.78 - $1.68 $20,443 - $44,032
-26,210 Reduced 57.58%
19,313 $15,000
Q3 2022

Nov 14, 2022

SELL
$1.59 - $2.74 $132,839 - $228,918
-83,547 Reduced 64.73%
45,523 $71,000
Q2 2022

Aug 15, 2022

BUY
$1.56 - $3.25 $50,392 - $104,984
32,303 Added 33.38%
129,070 $231,000
Q1 2022

May 16, 2022

SELL
$1.61 - $5.2 $51,784 - $167,252
-32,164 Reduced 24.95%
96,767 $307,000
Q4 2021

Feb 14, 2022

SELL
$2.87 - $6.29 $7,364 - $16,140
-2,566 Reduced 1.95%
128,931 $390,000
Q3 2021

Nov 15, 2021

SELL
$4.91 - $9.07 $2.44 Million - $4.5 Million
-495,991 Reduced 79.04%
131,497 $819,000
Q2 2021

Aug 16, 2021

BUY
$7.82 - $13.8 $2.04 Million - $3.6 Million
260,780 Added 71.11%
627,488 $5.35 Million
Q1 2021

May 17, 2021

SELL
$13.0 - $19.34 $3.17 Million - $4.72 Million
-243,837 Reduced 39.94%
366,708 $5.62 Million
Q4 2020

Feb 16, 2021

BUY
$13.03 - $17.09 $436,244 - $572,173
33,480 Added 5.8%
610,545 $9.86 Million
Q3 2020

Nov 16, 2020

BUY
$12.67 - $23.19 $5.76 Million - $10.5 Million
454,864 Added 372.23%
577,065 $8.06 Million
Q2 2020

Aug 14, 2020

SELL
$12.52 - $23.45 $1.87 Million - $3.5 Million
-149,179 Reduced 54.97%
122,201 $2.6 Million
Q1 2020

May 15, 2020

BUY
$11.4 - $27.28 $1.14 Million - $2.74 Million
100,308 Added 58.63%
271,380 $4.49 Million
Q4 2019

Feb 14, 2020

BUY
$9.68 - $18.67 $1.08 Million - $2.08 Million
111,507 Added 187.2%
171,072 $2.65 Million
Q2 2019

Aug 14, 2019

BUY
$17.07 - $18.84 $1.02 Million - $1.12 Million
59,565 New
59,565 $1.12 Million

Others Institutions Holding BCEL

About Atreca, Inc.


  • Ticker BCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,876,000
  • Description
  • Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...
More about BCEL
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.